美国 · SEC FORM 4
HERON THERAPEUTICS, INC. /DE/
HRTX · Nasdaq · CIK 0000818033 · Healthcare · Biotechnology
内部人信号
0 qualifying P purchase groups
当前 180 天评分窗口
29 同一窗口内观察到的 Form 4 交易行
0 sales · 29 期权、代扣税、授予、赠与或其他交易行
为什么没有活跃信号?
评分构成
活跃窗口内没有合资格买入,因此不计算分数。缺失的输入不会被当作零分或看空信号。
为什么没有分数?
- 没有合资格公开市场买入可提供聚集度、规模、角色、近期性或确信度输入。
- 卖出及其他 Form 4 活动继续作为背景显示,不会形成负分。
卖出和其他 Form 4 活动会单独显示,不会形成负面买入信号。没有买入不会被评分为看空。
买方广度、集中度与聚集买入
合资格买入进入 180 天研究窗口后,这些模块才会启用。
内部人活动时间轴
申报人轨道展示最近 180 天。符号形状区分交易类型;卖出仅作为背景。
—
信号历史
Scores are archived only when the company qualifies for a published US buy-signal snapshot. 最近一次合资格买入: 2025-08-08 · Rosen David Efraim; Rubric Capital Management LP.
近期 Form 4 活动
P is an open-market or private purchase. S is a sale. M, F, A and G usually describe exercises, tax withholding, awards and gifts. These categories remain visually separate.
市场背景
该股票尚未获取市场背景。每日任务会轮转处理美国股票池。
空头余额
空头余额是券商向 FINRA 申报的外部背景数据,不影响内部人信号。
- 空头股数
- 46,021,379
- 上期报告
- 43,380,273
- 日均成交量
- 2,660,297
- 回补天数
- 17.3
FINRA 结算日:2026-09-30 · 获取日期 2026-10-12 · FINRA 股票空头余额 ↗. 这是股数,每月两个结算日之后约一周公布;不是占已发行股份的比例。
历史股票买入
Qualifying code P transactions in the local Form 4 history, including purchases outside the current signal window.
| Transaction date | Reporting owner | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2025-08-08 | Rosen David Efraim; Rubric Capital Management LP | 买入 (P) | Common Stock, par value $0.01 per share ("Common Stock") | 2,387,225 | USD 1.50 | USD 3,580,838 | SEC 申报 ↗ |
| 2025-08-08 | Morgan Adam | 买入 (P) | Common Stock | 1,766,546 | USD 1.50 | USD 2,649,819 | SEC 申报 ↗ |
| 2023-11-17 | Forbes William P | 买入 (P) | Common Stock | 25,000 | USD 1.09 | USD 27,250 | SEC 申报 ↗ |
| 2023-11-16 | Forbes William P | 买入 (P) | Common Stock | 50,000 | USD 0.94 | USD 47,000 | SEC 申报 ↗ |
| 2023-11-16 | Duarte Ira | 买入 (P) | Common Stock | 85,000 | USD 0.89 | USD 75,650 | SEC 申报 ↗ |
| 2023-11-16 | Collard Craig A | 买入 (P) | Common Stock | 150,000 | USD 0.92 | USD 138,000 | SEC 申报 ↗ |
| 2023-07-21 | Morgan Adam | 买入 (P) | Common Stock, par value $0.01 per share | 2,486,744 | USD 1.37 | USD 3,406,839 | SEC 申报 ↗ |
Form 4 申报证据
52 transaction lines in the latest 365-day window; 298 in local history.
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | Hensley Mark Earl | 期权行权/转换 (M) | Common Stock | 31,250 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-06 | Hensley Mark Earl | 代扣税 (F) | Common Stock | 8,888 | USD 0.50 | USD 4,444 | SEC 申报 ↗ |
| 2026-07-31 | Hensley Mark Earl | 期权行权/转换 (M) | Common Stock | 11,769 | USD — | USD — | SEC 申报 ↗ |
展开近期 Form 4 证据 (30 grouped rows)
| 日期 | 申报人 | 类型 | 证券 | 股数 | 平均价格 | 估算金额 | 来源 |
|---|---|---|---|---|---|---|---|
| 2026-08-06 | Hensley Mark Earl | 期权行权/转换 (M) | Common Stock | 31,250 | USD — | USD — | SEC 申报 ↗ |
| 2026-08-06 | Hensley Mark Earl | 代扣税 (F) | Common Stock | 8,888 | USD 0.50 | USD 4,444 | SEC 申报 ↗ |
| 2026-07-31 | Hensley Mark Earl | 期权行权/转换 (M) | Common Stock | 11,769 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-31 | Forbes William P | 期权行权/转换 (M) | Common Stock | 11,694 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-31 | Forbes William P | 代扣税 (F) | Common Stock | 3,326 | USD 0.50 | USD 1,663 | SEC 申报 ↗ |
| 2026-07-31 | Duarte Ira | 期权行权/转换 (M) | Common Stock | 11,694 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-31 | Duarte Ira | 代扣税 (F) | Common Stock | 3,326 | USD 0.50 | USD 1,663 | SEC 申报 ↗ |
| 2026-07-31 | Collard Craig A | 期权行权/转换 (M) | Common Stock | 34,789 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-30 | Forbes William P | 期权行权/转换 (M) | Common Stock | 11,769 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-30 | Forbes William P | 代扣税 (F) | Common Stock | 3,348 | USD 0.50 | USD 1,674 | SEC 申报 ↗ |
| 2026-07-30 | Duarte Ira | 期权行权/转换 (M) | Common Stock | 13,535 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-30 | Duarte Ira | 代扣税 (F) | Common Stock | 3,850 | USD 0.50 | USD 1,925 | SEC 申报 ↗ |
| 2026-07-30 | Collard Craig A | 期权行权/转换 (M) | Common Stock | 50,021 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-19 | Forbes William P | 期权行权/转换 (M) | Common Stock | 3,874 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-19 | Forbes William P | 代扣税 (F) | Common Stock | 1,101 | USD 0.47 | USD 517 | SEC 申报 ↗ |
| 2026-07-19 | Duarte Ira | 期权行权/转换 (M) | Common Stock | 3,874 | USD — | USD — | SEC 申报 ↗ |
| 2026-07-19 | Duarte Ira | 代扣税 (F) | Common Stock | 1,101 | USD 0.47 | USD 517 | SEC 申报 ↗ |
| 2026-07-19 | Collard Craig A | 期权行权/转换 (M) | Common Stock | 13,797 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-16 | Duarte Ira | 期权行权/转换 (M) | Common Stock | 12,500 | USD — | USD — | SEC 申报 ↗ |
| 2026-06-16 | Duarte Ira | 代扣税 (F) | Common Stock | 3,555 | USD 0.38 | USD 1,351 | SEC 申报 ↗ |
| 2026-06-06 | Forbes William P | 期权行权/转换 (M) | Common Stock | 12,500 | USD — | USD — | SEC 申报 ↗ |
| 2026-05-06 | Hensley Mark Earl | 期权行权/转换 (M) | Common Stock | 125,000 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-30 | Hensley Mark Earl | 期权行权/转换 (M) | Common Stock | 11,770 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-30 | Forbes William P | 期权行权/转换 (M) | Common Stock | 23,464 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-30 | Duarte Ira | 期权行权/转换 (M) | Common Stock | 25,229 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-30 | Collard Craig A | 期权行权/转换 (M) | Common Stock | 84,810 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-19 | Forbes William P | 期权行权/转换 (M) | Common Stock | 3,874 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-19 | Duarte Ira | 期权行权/转换 (M) | Common Stock | 3,874 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-19 | Collard Craig A | 期权行权/转换 (M) | Common Stock | 13,797 | USD — | USD — | SEC 申报 ↗ |
| 2026-04-03 | Collard Craig A | 期权行权/转换 (M) | Common Stock | 62,500 | USD — | USD — | SEC 申报 ↗ |
Multiple price lines in one filing are grouped and share-weighted. Price and value are blank when a grouped filing line lacks price evidence.
快照与身份
| 快照日期 | 2026-10-19 |
|---|---|
| 排名版本 | US-v1.2 |
| 数据质量 | PASS ELIGIBLE · — |
| 股票代码 | HRTX |
| CIK | 0000818033 |
| 行业 | Healthcare |
| 细分行业 | Biotechnology Yahoo Finance |
| SEC SIC | 2834 Pharmaceutical Preparations |
| 交易所 | Nasdaq |
数据覆盖
| 本地 Form 4 历史 | 298 transaction lines from 2020-01-06 to 2026-08-06 7 P purchase lines · 14 S sale lines · 277 other lines |
|---|---|
| SEC 公司申报 | 打开 SEC 申报 ↗ |
Local ledger as of 2026-10-19. Mapping status is an audit field and does not erase SEC filing evidence.